Advocates Bash 'Junk Science' As Appeals Court Blocks Abortion Pill by Mail
Summary
A federal appeals court in New Orleans blocked a rule that allowed the abortion pill mifepristone to be delivered through the mail. The court’s decision is temporary and ongoing as the FDA reviews the medication’s safety, while pro-choice advocates warn this could limit abortion access.Key Facts
- A three-judge panel in New Orleans stopped the mailing of mifepristone, an abortion drug, under a 2023 federal rule.
- The court said the FDA did not provide enough scientific evidence to remove a rule requiring in-person dispensing of the drug.
- Louisiana challenged the 2023 rule in an effort seen by some as a way to limit abortion access.
- The ruling is temporary and will remain until the court fully decides on the case, which may take months.
- The FDA is reviewing the safety of mifepristone, with a decision expected after the November midterm elections.
- Pro-choice groups describe mifepristone as safe, effective, and necessary for accessible abortion care.
- They also say restricting mail distribution blocks telehealth access, which is often essential for those with limited options.
- The case may go to the U.S. Supreme Court as advocates and officials prepare for further legal battles.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
